NCT04555044View on ClinicalTrials.gov

Pediatric Study to Evaluate Risk of Developing Essential Fatty Acid Deficiency When Receiving Clinolipid or Standard-of-Care Lipid Emulsion (Part A)

PHASE4CompletedINTERVENTIONAL
Enrollment

101

Participants

Timeline

Start Date

January 22, 2021

Primary Completion Date

October 16, 2022

Study Completion Date

November 16, 2022

Conditions
Essential Fatty Acid Deficiency (EFAD)
Interventions
DRUG

Clinolipid

Lipid injectable emulsion, USP 20%

DRUG

Intralipid

Standard-of-Care Soybean Oil-Based Lipid Emulsion. 20% (lipid injectable emulsion, USP)

Trial Locations (9)

27834

Baxter Investigational Site, Greenville

32803

Baxter Investigational Site, Orlando

36604

Baxter Investigational Site, Mobile

38163

Baxter Investigational Site, Memphis

39216

Baxter Investigational Site, Jackson

78229

Baxter Investigational Site, San Antonio

84604

Baxter Investigational Site, Provo

06520

Baxter Investigational Site, New Haven

09111

Baxter Investigational Site, Boston

All Listed Sponsors
lead

Baxter Healthcare Corporation

INDUSTRY

NCT04555044 - Pediatric Study to Evaluate Risk of Developing Essential Fatty Acid Deficiency When Receiving Clinolipid or Standard-of-Care Lipid Emulsion (Part A) | Biotech Hunter | Biotech Hunter